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Abstract
Natural killer T cells recognize lipid antigens in the context of CD1 molecules. Recent publications
show that this mode of recognition differs substantially from that of classic T-cell receptor peptide-
major histocompatibility complex interaction.
Introduction and context
The recognition of lipids and glycolipids by the immune
system was exclusively focused on antibody production
until Brenner's group [1] described the recognition of
mycobacterial lipids by human ab T cells restricted on
CD1b. Until then, the common admission was that
T cells were tolerized against the main lipid components
of cells and lipid mediators; the possible recognition of
foreign lipids by CD4 or CD8 T cells was not even
considered. The admission that CD1 molecules [2] may
bind lipid was not settled until the first structure of a
CD1 molecule revealed an antigen-binding groove
unsuited to peptide binding [3] but ideal for lipid
interactions as it is lined with hydrophobic residues [4].
During the same period, it was discovered that natural
killer T (NKT) cells were restricted on CD1 [5] and that a
natural product extracted from marine sponge could
stimulate NKT cells in a CD1-restricted manner [6]. This
situation shifted the entire field of anti-lipid immunity
from the recognition of lipid/CD1 complexes by classical
ab and gd T cells toward the exclusive niche of NKT
biology and semi-invariant T-cell recognition. This
choice has proven very beneficial by concentrating the
effort on a very simplified model system. Indeed, NKT
cells are innate regulatory T cells essential for the initial
coordination of immune responses. As such, they express
a semi-invariant T-cell receptor (TCR), which certain
consider a pattern recognition receptor [7,8], made of a
unique a chain conserved between species (Va14 in
mice and Va24 in humans) and a limited set of Vb chains
(8.2, 7, and 2 in mice and 11 in humans). Serendipity
brought an unusual exogenous agonist of NKT, alpha-
galactosylceramide (aGalCer), to the field that allowed,
in sequence, the development of CD1 tetramers capable
of detecting NKT cells and the discovery of similar
bacterial ligands capable of stimulating NKT during the
course of infection. These developments were vital for
the rapid advances in the field of cellular immunology
of NKT cells as well as chemistry of NKT ligands and
structural biology of CD1 and semi-invariant TCR. The
search for endogenous ligands that drive thymic selec-
tion as well as normal innate stimulation of NKT cells
during the course of immune responses has remained
more elusive and brings forward some critical structural
considerations that will be discussed in the concluding
paragraph.
Major recent advances
Our understanding of the recognition of CD1 lipid
complexes by semi-invariant TCR has progressed rapidly
over the past 2 years with the determination of
CD1/aGalCer structures [9,10], Va14 and Va24 TCR
structures [11,12], and finally the uncovering of the
Va24/CD1 aGalCer complex structure [8,13]. We need
to keep in mind that most of our knowledge is focused
on the recognition of aGalCer and aGalCer-like ligands,
a family of exogenous antigens found only in Sphingo-
monas, Ehrlichia, and probably a very limited set of other
bacteria [14,15].
On the CD1 side, the mode of binding of phospholipids
and glycolipids is now well understood and appears to
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for TCR interaction, and its orientation is critically
influenced by the chemical nature of its linkage to the
acyl chains (glycerol versus ceramide and a versus b). The
acyl chains of the lipid occupy the groove of the CD1
molecule and impose some discrete but noticeable
conformational changes of the groove [10,17] that may
influence T-cell recognition to some extent [18].
The structures of Va24 and Va14 TCRs alone were
as expected for ab TCR and only confirmed the high
homology between human and murine receptors
[11,12]. The architecture of the Va24 TCR/CD1-aGalCer
revealed a dramatic parallel docking of TCR over CD1 at
the very end of its binding groove, an arrangement never
seen before; this footprint placed the complementarity-
determining regions (CDRs) of the a chain next to the
protruding a-linked galactose of the ligand [13]. One
should not overreact about this apparently unusual
docking or try to over-interpret it. Indeed, the more
TCR/major histocompatibility complex (MHC) struc-
tures we have, the more variations we see in the overall
mode of docking, with some extreme situations now
described for MHC class II/TCR complexes. These great
variations in docking batter, to some extent, the concept
of genomic ‘interaction codons’ that was developed for
Vb8.2 TCR/peptide-MHC recognition [20] since the
Vb8.2 of NKT receptors does not respect that same
recognition mode. However, the most important finding
brought about by the elucidation of the first Va24
TCR/CD1-aGalCer and now Va14 TCR/CD1-aGalCer
structures is the ideal placement of the a chain next to
the galactose of aGalCer and the dominance of recogni-
tion by CDR1 and CDR3a loops. Interestingly enough,
these structures also revealed that the b chain is playing
some accessory role in binding by revealing the
participation of the CDR2b and CDR3b loops in the
overall footprint. Given the sequence similarities
between CDR2b of Vb8.2 and Vb7, the influence of
single-residue mutagenesis was evaluated with respect to
TCR/CD1 affinity. Whereas the higher affinity of the
Vb8.2 retaining TCR could not be improved, a single
change in Vb7 (S54→A) was capable of increasing the
affinity four-fold, indicating that the CDR2b of Vb7 was
suboptimal. However, it is too early to conclude that this
affinity difference is sufficient to explain the preferential
usage of Vb8 over Vb7 in the mouse NKT repertoire.
Indeed, if one looks at the human system where Vb11 is
used almost exclusively, TCR/CD1-aGalCer has a much
lower affinity than its murine counterpart, and it is likely
that some other Vb could pair just as well with Va24 to
achieve such a low-affinity interaction; but they do not.
More importantly, measurements carried out with
aGalCer as the CD1-bound ligand might have no
relevance to the thymic situation and repertoire selection
of NKT cells. Indeed, this process will be driven by CD1
bound to natural unknown ligands which might have
no chemical relationship to aGalCer whatsoever. It is
still interesting to argue the opposite situation (that the
CD1-aGalCer measurements are relevant) and propose
that lipid recognition by semi-invariant TCR will obey
the same set of rules for binding independently of the
CD1-bound lipid. The fact that the hierarchy of Vb usage
is identical for hybridomas stimulated with CD1a-
GalCer and CD1-iGb3 (CD1 isoglobotrihexosylcera-
mide) may support the argument [21]. However, again,
caution is required as different approaches have come
to different conclusions and were arguing that the
repertoire of CD1-iGb3-reactive cells was much more
restricted than that of aGalCer-restricted cells [22].
Future directions
Have all of the questions regarding the semi-invariant
TCR recognition of CD1 lipid complexes been answered?
Of course not, even though it is clear that for the
particular ligand that is aGalCer, we have a very good
understanding of the molecular events that led to its
detection. However, two essential paradigms remain
poorly understood and largely unexplored and will
require attention and investment: (a) the recognition of
CD1 lipid complexes by non-semi-invariant TCR and (b)
the recognition of endogenous selecting and activating
ligands. With respect to point (a), it is important to
remember that the recognition of bacterial lipids in a
CD1-restricted manner by ‘normal’ ab and gd T cells was
the first established link between lipids and T cells [1].
Ever since, the recognition of exogenous lipids by T cells
has not been studied as extensively. The main reasons for
this situation are simple: lack of reagents (for example,
tetramers or animal models [23]) and the inability to
immunize efficiently against lipids. Consequently, we
do not know how to efficiently expand these T-cell
populations in vivo, and even if we did, we would be
unable to follow them. The second challenge faced by
researchers in the field is just as daunting: discovering
endogenous ligands. As compelling as the argument is
about iGb3 being one of the endogenous NKT ligands
[24], it is quite obvious that other ligands remain to be
discovered. However, what is not obvious is the
approach amenable to their discovery. Genetic analysis
has proven unfruitful, with the exception of iGb3, and
biochemistry and direct isolation are mostly limited by
the fact that we do not know what we are looking for
(a classic chicken-egg problem in lipid chemistry). At this
point, new screening methods must be explored or we
will all have to hope that serendipity strikes again like it
did in the discovery of aGalCer.
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